In fact, many recurrent oncogeneic fusions that have been shown to drive cancer evolution—such as BCR-ABL1 in CML—involve constitutive kinase expression or activation, which enhances downstream signalling pathways and elevates the rate of cell division [170,171,172]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.